Therapy » Mucoactive drugs in the treatment of patients with acute and chronic respiratory pathology

Mucoactive drugs in the treatment of patients with acute and chronic respiratory pathology

DOI: https://dx.doi.org/10.18565/therapy.2024.6.104-110

Prozorova G.G., Budnevsky A.V., Chernik T.A.
N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia

Abstract. Adjusting of pharmacological therapy for cough-manifesting respiratory diseases treatment may require a multi-stage diagnostic search. To increase the efficacy of sputum discharge in case of productive cough, patients are prescribed mucoactive drugs, which are divided into several pharmacological groups. The article highlights current data concerning possible therapeutic approaches to cough treatment, and presents two clinical observations illustrating the principles of choosing therapy for acute and chronic diseases of the bronchopulmonary system, accompanied by productive cough.

Keywords: erdosteine, mucolytics, acute bronchitis, cough, chronic obstructive pulmonary disease

Read entire article

Literature

1. Зайцев А.А., Оковитый С.В. Кашель: от основ к фармакотерапии. Consilium Medicum. 2020; 22(11): 72–77. (Zaitsev A.A., Okovityi S.V. Cough: from basics to pharmacotherapy. Consilium Medicum. 2020; 22(11): 72–77 (In Russ.)).

https://doi.org/10.26442/20751753.2020.11.200523. EDN: CEBANM.

2. Суханов Д.С., Алексеева Ю.С., Коршунова А.Л. Подходы к диагностике и терапии кашля в терапевтической практике. Лечащий врач. 2023; 26(6): 83–89. (Sukhanov D.S., Alekseeva Yu.S., Korshunova A.L. Approaches to the diagnosis and therapy of cough in therapeutic practice. Lechaschiy vrach = Attending Physician. 2023; 26(6): 83–89 (In Russ.)).

https://doi.org/10.51793/OS.2023.26.6.0122. EDN: AILMFG.

3. Оковитый С.В., Марьюшкина В.С., Суханов Д.С. с соавт. Фармакологические подходы к рациональному выбору комбинированных мукоактивных препаратов. Лечащий врач. 2020; (12): 41–45. (Okovityj S.V., Mar’jushkina V.S., Sukhanov D.S. et al. Pharmacological approaches to the rational choice of combined mucoactive drugs. Lechaschiy vrach = Attending Physician. 2020; (12): 41–45 (In Russ.)).

https://doi.org/10.26295/OS.2020.95.33.009. EDN: OHGGUI.

4. Зайцев А.А., Оковитый С.В. Кашель: дифференциальный диагноз и рациональная фармакотерапия. Терапевтический архив. 2014; 86(12): 85–91. (Zaitsev A.A., Okovityi S.V. Cough: Differential diagnosis and rational pharmacotherapy. Terapevticheskiy arkhiv = Therapeutic Archive. 2014; 86(12): 85–91 (In Russ.)).

https://doi.org/10.17116/terarkh2014861285-91. EDN: TMPMCJ.

5. Poole P., Sathananthan K., Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019; 5(5): CD001287.

https://doi.org/10.1002/14651858.CD001287.pub6. PMID: 31107966. PMCID: PMC6527426.

6. Raghu G., Berk M., Campochiaro P.A. et al. The multifaceted therapeutic role of n-acetylcysteine (NAC) in disorders characterized by oxidative stress. Curr Neuropharmacol. 2021; 19(8): 1202–24.

https://doi.org/10.2174/1570159X19666201230144109. PMID: 33380301. PMCID: PMC8719286.

7. Княжеская Н.П., Бобков Е.В. Современная муколитическая терапия заболеваний дыхательных путей. РМЖ. 2018; 26(3-1): 30–35. (Knyazheskaya N.P., Bobkov E.V. Modern mucolytic therapy of respiratory tract diseases. Rossiyskiy meditsinskiy zhurnal = Russian Medical Journal. 2018; 26(3-1): 30–35 (In Russ.)). EDN: YVMOWE.

8. Franova S., Kazimierova I., Pappova L. et al. The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation. Pulm Pharmacol Ther. 2019; 54: 60–67.

https://doi.org/10.1016/j.pupt.2018.11.006. PMID: 30502381.

9. Rogliani P., Matera M.G., Page C. et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019; 20(1): 104.

https://doi.org/10.1186/s12931-019-1078-y. PMID: 31133026. PMCID: PMC6537173.

10. Park J.S., Park M.Y., Cho Y.J. et al. Anti-inflammatory effect of erdosteine in lipopolysaccharide-stimulated RAW 264.7. cells. Inflammation. 2016; 39(4): 1573–81.

https://doi.org/10.1007/s10753-016-0393-4. PMID: 27317418.

11. Ricevuti G., Mazzone A., Uccelli E. et al. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988: 43(8): 585–90.

https://doi.org/10.1136/thx.43.8.585. PMID: 3051508. PMCID: PMC461392.

12. Dal Negro R., Pozzi E., Cella S.G. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases. Pulm Pharmacol Ther. 2018; 53: 80–85.

https://doi.org/10.1016/j.pupt.2018.10.005. PMID: 30352285.

13. Strizzi S., Danzo F., Vanetti C. et al. Antiviral and anti-inflammatory effects of erdosteine and MET-1 in SARS-CoV-2 in vitro infection. Eur Respir J. 2023; 62: PA1682.

https://doi.org/10.1183/13993003.congress-2023.PA1682.

14. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2022. Report. URL: https://goldcopd.org/2022-gold-reports (date of access – 12.08.2024).

15. Клинические рекомендации. Острый бронхит у взрослых. Межрегиональная общественная организация «Российское респираторное общество», общероссийская общественная организация «Российское научное медицинское общество терапевтов», межрегиональная ассоциация специалистов респираторной медицины (МАСРМ). 2022. Доступ: https://spulmo.ru/upload/kr/OB_2022.pdf (дата обращения – 12.08.2024). (Clinical guidelines. Acute bronchitis in adults. Russian Respiratory Society, Russian Scientific Medical Society of Internal Medicine, Interregional Association of Respiratory Medicine Specialists (IARMS). 2022. URL: https://spulmo.ru/upload/kr/OB_2022.pdf (date of access – 12.08.2024) (In Russ.)).

16. Клинические рекомендации. Хронический бронхит. Межрегиональная общественная организация «Российское респираторное общество». Рубрикатор клинических рекомендаций Минздрава России. 2023. ID: 655. Доступ: https://cr.minzdrav.gov.ru/recomend/655_1 (дата обращения – 12.08.2024). (Clinical guidelines. Chronic bronchitis. Russian Respiratory Society. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2023. ID: 655. URL: https://cr.minzdrav.gov.ru/recomend/655_1 (date of access – 12.08.2024) (In Russ.)).

About the Autors

Galina G. Prozorova, MD, Dr. Sci. (Medicine), associate professor, professor of the Department of therapeutic disciplines of the Institute of continuing professional education, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya St.
E-mail: ovp.idpo@vrngmu.ru
ORCID: https://orcid.org/0000-0001-8675-1590
Andrey V. Budnevsky, MD, Dr. Sci. (Medicine), professor, head of the Department of faculty therapy, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia, Honored Inventor of the Russian Federation. Address: 394036, Voronezh, 10 Studencheskaya St.
E-mail: avbudnevski@vrngmu.ru
ORCID: https://orcid.org/0000-0002-1171-2746
Tatyana A. Chernik, MD, PhD (Medicine), assistant at the Department of faculty therapy, N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of Russia. Address: 394036, Voronezh, 10 Studencheskaya St.
E-mail: ch01@mail.ru
ORCID: https://orcid.org/0000-0003-1371-0848

Mucoactive drugs in the treatment of patients with acute and chronic respiratory pathology

Literature

About the Autors

Similar Articles